LOGIN  |  REGISTER
Surmodics

Latest Life Science Financial Results & Earnings

Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase

May 23
Last Trade: 82.29 0.91 1.12

Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Heart; gaining momentum as company enters new product cycles across many high-growth markets DUBLIN, May 23, 2024 /CNW/ -- Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024. Key Highlights Q4...Read more


CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

May 23
Last Trade: 3.69 -0.28 -7.05

Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSK Settlement with Acuitas Therapeutics includes acknowledgment of CureVac's ownership of certain patent claims and Acuitas's licenses to selected...Read more


Calliditas Therapeutics Q1 report, January - March 2024

May 23
Last Trade: 22.42 -0.33 -1.45

STOCKHOLM, May 23, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALTX) (STOCKHOLM: CALTX): Target market expansion following full approval in the US JANUARY - MARCH 2024 (COMPARED TO JANUARY - MARCH 2023) Net sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the three months ended March 31, 2023, net sales amounted to SEK...Read more


23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

May 23
Last Trade: 0.51 0.0036 0.71

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review...Read more


Premier Health Reports 2024 Second Quarter Results

May 23
Last Trade: 0.33 -0.07 -17.50

MONTRÉAL, May 23, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its Unaudited Quarterly Consolidated Financial Statements and MD&A for its second quarter ended on March 31st, 2024. Highlights (in thousands of Canadian dollars) Mar. 31, 2024(3 months) Mar. 31, 2023(3 months) Mar. 31, 2024(6 months) Mar. 31, 2023(6...Read more


Kane Biotech Announces First Quarter 2024 Financial Results

May 23
Last Trade: 0.13 -0.02 -13.33

WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results. The Company previously announced on April 11, 2024 that it had reached an agreement in principle for the sale of its entire interest in STEM Animal Health Inc. (“STEM”) to a third party multi-national pharmaceutical company on a cash-free debt-free...Read more


Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance

May 23
Last Trade: 1.69 0.06 3.68

Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025 Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and scaling of HIV test production Disciplined execution of operational efficiencies led to 3.6 percentage point Q/Q increase in gross margin percentage with further...Read more


Newtopia Reports Fourth Quarter, Full Year 2023 and First Quarter 2024 Financial Results

May 23
Last Trade: 0.07 0.00 0.00

Newtopia is emboldened by our immediate growth prospects based on three exciting developments in the market: Growth of GLP-1s opens a huge market for Newtopia to demonstrate sustainability and ROI. Rise of Health AI and next-gen clinical discovery requires Newtopia's novel data and capabilities. Expansion opportunities with Heartland Whole Health Institute based on Newtopia's best-ever reported outcomes. TORONTO, May 23,...Read more


Evotec Reports Q1 2024 Results and Provides Corporate Update

May 22
Last Trade: 4.77 -0.16 -3.25

CHALLENGING Q1 WITH SOFTNESS MAINLY IN TRANSACTIONAL/DEVELOPMENT SHARED R&D BUSINESS AGAINST A STRONG COMPARABLE QUARTER STRONG START WITH JUST - EVOTEC BIOLOGICS IN Q1 2024 POSITIVE MOMENTUM IN SHARED R&D DISCOVERY CLOSED SALES POINT TO RECOVERY OF REVENUES TOWARDS END OF THE YEAR RESET FOR PROFITABLE GROWTH INITIATED, NEW REPORTING SEGMENTS INTRODUCED: SHARED R&D AND JUST - EVOTEC BIOLOGICS HAMBURG, GERMANY /...Read more


Auna Announces 1Q24 Financial Results

May 22
Last Trade: 8.21 0.00 0.00

Revenue increases 20% YoY to S/1,076 million, with operating profit increasing 26% to S/182 million Adjusted EBITDA margin of 20.4% in Peruvian operations LUXEMBOURG / May 22, 2024 / Business Wire / Auna (NYSE: AUNA) (“Auna” or the “Company”), one of the largest and most recognized company in Latin America’s healthcare industry with operations in Mexico, Colombia and Peru, today announced unaudited financial results for the three...Read more


Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

May 21
Last Trade: 14.19 0.61 4.49

Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline...Read more


Exscientia Business Update for First Quarter 2024

May 21
Last Trade: 4.69 -0.04 -0.85

Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and streamlining...Read more


LAVA Therapeutics Provides Business Updates and Reports First Quarter 2024 Financial Results

May 21
Last Trade: 2.64 0.00 0.00

LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND submission Strong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE...Read more


Purple Biotech Reports First Quarter 2024 Financial Results

May 21
Last Trade: 0.75 -0.06 -6.88

REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024. “We look forward to presenting compelling interim Phase 2 CM24 data...Read more


BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

May 21
Last Trade: 0.34 -0.0048 -1.39

Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025 Company will host a conference call and webcast today at 8:00 am ET GAITHERSBURG, Md. and NESS ZIONA, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...Read more


Orgenesis Provides Business Update for the First Quarter of 2024

May 21
Last Trade: 0.48 -0.005 -1.03

GERMANTOWN, Md., May 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the first quarter ended March 31, 2024. Vered Caplan, CEO of Orgenesis, said, “We continue to advance the commercialization of our...Read more


Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%

May 21
Last Trade: 0.76 0.01 1.75

NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 first quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $7,541,046 for the quarter ended March 31, 2024, a 54%...Read more


Mobile-health Network Solutions Revenue Rises Approximately 120% in the First Six Months of Fiscal 2024

May 21
Last Trade: 1.80 0.00 0.00

SINGAPORE, May 21, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced that for the first six months of fiscal 2024 (“H1FY24”) ended December 31, 2023, the Company had revenue of approximately $6.6 million, approximately a 120% improvement on revenue of $3.0 million for the same period in fiscal 2023 (“H1FY23”). Telemedicine...Read more


Taro Pharmaceutical Provides Results for Year Ended March 31, 2024

May 20
Last Trade: 42.69 -0.06 -0.14

HAWTHORNE, N.Y. / May 20, 2024 / Business Wire / Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compared to March 31, 2023 Net sales of $164.9 million increased $18.4 million, or 12.5%, principally due to new launches and gross-to-net (“GTN”) adjustments. Excluding the impact of...Read more


Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 20
Last Trade: 2.53 -0.12 -4.53

Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow  First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada  Patient recruitment for ReSTART U.S. multi-center pivotal trial and for pancreatic cancer feasibility and safety studies in Canada and Israel...Read more


Sol-Gel Technologies Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 20
Last Trade: 0.80 0.00 0.00

Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration of up to $115 million. Sol-Gel recently initiated a proof-of-concept study for SGT-210 (topical erlotinib) in patients with Darier disease. Highly encouraging clinical response...Read more


Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 17
Last Trade: 3.92 0.05 1.29

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 Market Authorization Application (MAA) for obe-cel in r/r adult ALL accepted by European Medicines Agency (EMA) Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call...Read more


StageZero Life Sciences Announces Q1 2024 Financial Results and Operational Update

May 17
Last Trade: 0.04 0.00 0.00

TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its first...Read more


Doximity Announces Fourth Quarter and Fiscal Year 2024 Financial Results

May 16
Last Trade: 27.83 0.42 1.53

Fiscal year 2024 total revenues of $475.4 million, up 13% year-over-year Fiscal year 2024 net income growth of 31% and adjusted EBITDA growth of 25% year-over-year Q4 total revenues of $118.1 million, up 6% year-over-year Q4 net income growth of 32% and adjusted EBITDA growth of 15% year-over-year SAN FRANCISCO / May 16, 2024 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals,...Read more


Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

May 16
Last Trade: 5.22 -0.44 -7.77

Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 Recent Type C CMC meeting with the U.S. Food and Drug Administration (FDA) supports IGNYTE Biologics License Application (BLA) submission expected in 2H 2024 Enrollment of first patients in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in 2H...Read more


EDAP TMS Reports First Quarter 2024 Financial Results

May 16
Last Trade: 6.12 0.21 3.55

Strong Q1 2024 U.S. Focal One® HIFU procedure growth of +92% year-over-year Q1 2024 HIFU revenue of EUR 5.8 million ($6.3 million USD), an increase of 10.2% over Q1 2023 Q1 2024 total revenue of EUR 14.9 million ($16.1 million USD) increased 0.8% over Q1 2023 Company to host conference call and webcast today, May 16th, at 8:30 a.m. EDT LYON, France, May 16, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic...Read more


Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

May 16
Last Trade: 3.81 0.00 0.00

MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being prepared Radio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into IND-enabling studies with partner Orano Med, preclinical data to be presented at SNMMI 2024 Switch-DARPin Platform: Initial data to be presented at EHA 2024; Preclinical proof-of-concept...Read more


NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates

May 16
Last Trade: 2.06 -0.03 -1.44

Target for completing enrollment of the chronic cohort in the Phase 1b/2a clinical trial moved to Q3 2024 Subacute cohort protocol being amended to enhance feasibility and lessen burden on participants CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a...Read more


BioSyent Releases Financial Results for Q1 2024

May 16
Last Trade: 9.15 -0.04 -0.44

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include:  (CAD) Q1 2024 % Change vs.Q1 2023 Trailing Twelve Months(TTM) March 31, 2024 % Change vs.TTMMarch 31, 2023 Canadian Pharma Sales 7,546,144 18 % 30,689,349 16 % International Pharma...Read more


CEL-SCI Reports Second Quarter Fiscal 2024 Financial Results

May 16
Last Trade: 1.24 -0.03 -2.36

VIENNA, Va. / May 16, 2024 / Business Wire / CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2024, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: In May 2024, CEL-SCI received the go-ahead from the U.S. Food and Drug Administration (FDA) for its confirmatory Registration Study of Multikine* in the treatment of head and neck...Read more


Milestone Scientific Reports Revenue of $2.2 Million and Provides Business Update for the First Quarter of 2024

May 16
Last Trade: 0.75 -0.02 -2.59

Sales through new online portal increase 31% over the same period last year Gross margin for the first quarter of 2024 increases to 74.5% from 72.7% for the same period last year Reports steady progress on reimbursement strategy for the CompuFlo® Epidural System ROSELAND, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide...Read more


Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 16
Last Trade: 1.35 0.05 3.85

Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025 GAINESVILLE, Fla. / May 16, 2024 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to...Read more


AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 16
Last Trade: 0.39 -0.01 -2.97

Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will...Read more


Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 16
Last Trade: 1.94 0.08 4.30

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio’s ADC Cancer Therapeutic Platform Technology and Akari’s PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible...Read more


Neupath Health Reports Record Quarterly Revenues With First Quarter 2024 Results

May 16
Last Trade: 0.18 0.01 5.88

Delivered record first quarter total revenue of $17.5 million, up 9% year-over-year Adjusted EBITDA(1) of $0.9 million, our 21st consecutive quarter of positive adjusted EBITDA Improved cash flows, closing cash and cash equivalents balance of $2.6 million, up more than 300% year-over-year TORONTO / May 16, 2024 / Business Wire / NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics...Read more


NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 16
Last Trade: 3.52 0.00 0.00

Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first...Read more


Exicure Reports Third Quarter 2023 Financial Results

May 16
Last Trade: 0.33 -0.12 -26.34

CHICAGO / May 16, 2024 / Business Wire / Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives...Read more


CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

May 16
Last Trade: 0.21 -0.0022 -1.02

Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025 Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX / ACCESSWIRE / May 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the...Read more


Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 16
Last Trade: 15.76 0.00 0.00

Contineum is focused on leading the Neuroscience, Inflammation and Immunology (NI&I) field Successful completion of Initial Public Offering with strong syndicate of existing and new investors SAN DIEGO / May 16, 2024 / Business Wire / Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways...Read more


Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15
Last Trade: 24.13 1.48 6.53

Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments of $434.8 million as of March 31, 2024, plus gross proceeds of $280 million from April private placement extends cash runway into...Read more


Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results

May 15
Last Trade: 1.49 -0.02 -1.32

Continued progress enrolling in its VMT-α-NET and VMT01 clinical trials Disclosed a new internally discovered molecule that targets fibroblast activation protein-α Announced the in-licensing of a technology that enables the use of antibodies to direct radiolabeled ligands to tumor sites Raised $177.2 million in gross proceeds through various financing transactions and raised an additional $49.5 million subsequent to March 31st under...Read more


Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 15
Last Trade: 13.99 6.79 94.31

U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D., to Chief Scientific Officer, Dennis Dean, Ph.D., to Chief Non-Clinical Development Officer, and the promotion of Jennifer Dittman to Chief Development Operations...Read more


Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 15
Last Trade: 10.92 -0.29 -2.59

No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials  Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials to be presented at a satellite symposium at the EULAR 2024 Congress in June  Evaluating CABA-201 without preconditioning by initiation of the RESET-PV™...Read more


Celcuity Reports First Quarter Financial Results and Provides Corporate Update

May 15
Last Trade: 15.64 -0.22 -1.39

The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024 First patient dosed in a Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer $177.7 million in cash, cash equivalents and short-term investments expected to provide runway into the first half of 2026...Read more


Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15
Last Trade: 2.95 0.02 0.68

LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its...Read more


Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

May 15
Last Trade: 7.79 -0.02 -0.26

Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024  Company entered into non-exclusive licensing agreement for use of its proprietary, muscle-targeted AAV-SLB101 capsid  Company ends first quarter 2024 with approximately $206.1 million in cash and investments.Solid has anticipated cash...Read more


atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

May 15
Last Trade: 1.61 -0.02 -1.23

First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24 Beckley Psytech’s Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b topline data expected in 2H’24 Compass Pathways’ Phase 2 study of COMP360 in PTSD patients demonstrated durable improvement in symptoms; Phase 3 data of COMP360 in TRD...Read more


Adaptimmune Therapeutics Reports Q1 2024 Financial and Business Updates

May 15
Last Trade: 1.05 0.04 3.96

Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to be...Read more


TriSalus Life Sciences Reports Q1 2024 Financial Results and Business Update

May 15
Last Trade: 7.56 -1.98 -20.75

Reported revenues of $6.5 million in 1Q24, up 116% compared to 1Q23 Reported gross margin of 85% in 1Q24 Secured up to $50 million of debt financing with OrbiMed to support TriNav® Infusion System growth initiatives Announced the appointment of Liselotte Hyveled to the Board of Directors Full year sales growth expected to exceed 50% Conference call May 15th at 9:00 a.m. EDT DENVER / May 15, 2024 / Business Wire / TriSalus Life...Read more


Omeros Reports First Quarter 2024 Financial Results

May 15
Last Trade: 3.35 0.06 1.82

Conference Call Today at 4:30 p.m. ET SEATTLE / May 15, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent...Read more


Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

May 15
Last Trade: 3.05 0.00 0.00

Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024 NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading...Read more


Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

May 15
Last Trade: 7.90 0.37 4.91

Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma) United Kingdom (UK) Marketing Authorization Application (MAA) submitted NORSE EIGHT fully underway in the US; Topline readout expected in Q4 CY2024 Resubmission of the ONS-5010 Biologics License Application (BLA) planned by the end of CY2024 Company to host inaugural...Read more


Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 15
Last Trade: 3.07 -0.04 -1.29

PALO ALTO, Calif., May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501 and KSI-101, as well as on our duet and triplet research programs," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We...Read more


CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15
Last Trade: 18.69 -0.24 -1.27

CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 Completed up to $149.4 million private placement with leading healthcare investors in early 2Q 2024  BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments...Read more


Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15
Last Trade: 4.82 0.12 2.55

Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024 End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) expected in the second quarter of 2024 Preparations are underway to start a pivotal Phase 3 trial evaluating denifanstat in patients with metabolic dysfunction-associated...Read more


Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 15
Last Trade: 3.56 0.50 16.34

Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology study in brown Norway rats; early results show no abnormalities at highest tested dose of RZ358 Continue to engage in productive interactions with FDA towards resolution of partial clinical holds and path forward for potential late-stage,...Read more


Quipt Home Medical Reports Second Quarter Fiscal 2024 Financial Results Posting Revenue Growth of 10% and Adjusted EBITDA Growth of 14%

May 15
Last Trade: 3.19 0.06 1.92

• Posts Adjusted EBITDA Margin of 23.3% as a % of Revenue • Announced Normal Course Issuer Bid (“NCIB”) Subsequent to Quarter End CINCINNATI, May 15, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S.-based home medical equipment provider, focused on end-to-end respiratory care, today announced its second quarter fiscal 2024 financial results and operational highlights. These...Read more


PDS Biotechnology Provides Business Update and Reports First Quarter 2024 Financial Results

May 15
Last Trade: 3.08 -0.04 -1.28

Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...Read more


Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress

May 15
Last Trade: 4.06 -0.11 -2.64

BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024 and recent corporate progress. “We are grateful to our existing as well as new investors who have demonstrated their support through the recent...Read more


Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 15
Last Trade: 2.64 0.08 3.12

Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease expected in second half of 2024  Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance sheet to support...Read more


FONAR Announces Fiscal 2024 Financial Results for 3rd Quarter and Nine-Month Period

May 15
Last Trade: 15.34 0.03 0.20

Total MRI scan volume at the HMCA-managed sites increased 11% to 154,790 scans for the nine-month period ended March 31, 2024 as compared to the nine-month period ended March 31, 2023. Net Income increased 25% to $12.5 million for the nine-month period ended March 31, 2024 as compared to the nine-month period ended March 31, 2023. Income from Operations for the nine-month period ended March 31, 2024 increased 24% to $15.2...Read more


Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance

May 15
Last Trade: 0.74 -0.03 -3.60

Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT / ACCESSWIRE / May 15, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $27.9 million, up 55%,...Read more


Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15
Last Trade: 8.41 -0.44 -4.97

ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading presented at the AACR Annual Meeting ELI-002 7P Phase 1 preliminary data to be presented at the ASCO Annual Meeting (“ASCO”) in June 2024 ELI-002 7P randomized Phase 2 trial enrollment expected to complete in fourth quarter 2024 BOSTON,...Read more


Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 15
Last Trade: 1.47 -0.01 -0.68

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI Received FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPA Cash balance of $82.3 million as of March 31, 2024; reiterate expected cash...Read more


Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 15
Last Trade: 3.56 -0.10 -2.73

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a...Read more


Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

May 15
Last Trade: 2.12 -0.11 -4.73

AUSTIN, Texas / May 15, 2024 / Business Wire / Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2024, and recent updates. Third...Read more


Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15
Last Trade: 12.02 0.10 0.84

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2024, and provided an update on its corporate...Read more


Envoy Medical Reports First Quarter 2024 Results

May 15
Last Trade: 2.76 -0.29 -9.51

The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant. WHITE BEAR LAKE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces...Read more


DarioHealth Reports First Quarter 2024 Financial and Operating Results

May 15
Last Trade: 1.76 0.16 10.00

First quarter revenue of $5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to the first quarter of 2023 due to milestone driven revenues. Core revenue channel B2B2C, employers and health plans recurring revenues in the first quarter totaled $3.47 million, an increase of 176% year over year and 210% sequentially from...Read more


Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update

May 15
Last Trade: 2.00 0.02 1.01

Second quarter fiscal 2024 revenue down 21.5% to $119.0 million Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million Agreement in principle reached with the U.S. Department of Justice on related matter Site optimization projects near completion Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research...Read more


Movano Health Reports Q1 2024 Financial Results and Provides Business Update

May 15
Last Trade: 0.45 -0.66 -59.51

Submits exemplary Sp02 clinical trial results as part of FDA 510(k) clearance process Plans launch of Evie Med and focuses on B2B opportunities Plans arterial blood pressure study for June Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., May 15, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported first quarter 2024 results and provided a business update. Following...Read more


Microbix Biosystems Reports Strong Results for Q2 Fiscal 2024

May 15
Last Trade: 0.32 -0.005 -1.54

MISSISSAUGA, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2024 ended March 31, 2024 (“Q2” and “H1”), with strong growth in sequential and year-over-year quarterly revenues, reflective of ongoing progress to increase sales from its diagnostic-test related...Read more


HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

May 15
Last Trade: 1.11 0.01 0.91

MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024.    Dr....Read more


iCAD Reports Financial Results for First Quarter Ended March 31, 2024

May 15
Last Trade: 1.58 -0.03 -1.86

NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024. First Quarter 2024 Highlights (Year over Year Performance): Total ARR was $9.0 million, up 10% Total revenues were $5.0 million, up...Read more


Acurx Pharmaceuticals Reports First Quarter 2024 Results and Provides Business Update

May 15
Last Trade: 2.51 -0.10 -3.83

STATEN ISLAND, N.Y., May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2024. Highlights of the first quarter ended March 31, 2024, or in some cases...Read more


Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol

May 15
Last Trade: 0.71 0.02 3.09

Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the first new ophthalmic steroid in 15 years, clobetasol propionate ophthalmic suspension 0.05%, for the treatment of inflammation and pain following ocular surgery Company to host conference call and webcast today, May 15th, at 4:30 pm...Read more


Oncocyte Reports First Quarter 2024 Financial Results

May 15
Last Trade: 2.83 -0.0044 -0.16

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Laboratories, Inc. On track to ship research use only (RUO) GraftAssure™ transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in...Read more


Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15
Last Trade: 4.14 0.07 1.72

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment Company received approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN)...Read more


Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 15
Last Trade: 1.87 0.03 1.63

Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO)...Read more


Palatin Technologies Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

May 15
Last Trade: 2.01 0.02 1.01

Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), at the12-Week Treatment Period Rapid Onset of Efficacy and Multiple Symptom Endpoints, Including the Co-Primary Pain Endpoint, Met Statistical Significance (P<0.05) at the 2-Week Treatment Period and Continued to...Read more


Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

May 15
Last Trade: 0.43 0.03 8.55

LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with...Read more


bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

May 15
Last Trade: 2.67 0.21 8.54

Expanded, experienced sales team more than doubles number of physician practices ordering CyPath® Lung test year-to-date More than 547% annualized growth rate for CyPath® Lung orders in first four months of 2024 over full-year 2023, leading to 35% increase in original 2024 forecast KOL referrals and word-of-mouth expanding adoption of CyPath® Lung outside of the beta market launch in Texas SAN ANTONIO / May 15, 2024 / Business Wire /...Read more


Aspira Women’s Health Reports First Quarter 2024 Financial Results

May 15
Last Trade: 2.29 -0.04 -1.72

Q1 2024 OvaSuiteSM revenue of $2.2 million and volume of 5,829 units Q1 2024 cash utilization of $4.4 million, a decrease of 22% compared to Q1 2023 Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic...Read more


Retractable Technologies Results for the Period Ended March 31, 2024

May 15
Last Trade: 0.94 0.0072 0.77

LITTLE ELM, Texas / May 15, 2024 / Business Wire / Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.6 million for the first three months of 2024 and an operating loss of nearly $3.0 million for the period, as compared to total net sales for the same period last year of $11.0 million and an operating loss of $2.7 million. The differences in the revenues and operating losses are largely due to the lack of...Read more


American Oncology Network Announces First Quarter 2024 Financial Results

May 15
Last Trade: 2.13 -0.06 -2.74

First Quarter 2024 Highlights Revenue of $364.3 million increased by 20.0% compared to the prior year quarter Patient encounter growth of 7.1% as compared to the prior year quarter Added 17 new providers to the AON platform Expanded in Texas and Maryland markets FORT MYERS, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- American Oncology Network, Inc. (NASDAQ: AONC), a leading oncology platform with an innovative model of...Read more


Scinai Immunotherapeutics Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 15
Last Trade: 4.14 0.46 12.46

JERUSALEM, May 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its full-year financial results for the year ended December 31, 2023, and provided a business update. Business Update &...Read more


Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15
Last Trade: 0.59 0.10 19.44

Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Biora...Read more


VBI Vaccines Reports First Quarter 2024 Financial Results

May 15
Last Trade: 0.65 0.02 3.02

PreHevbrio® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) announced in April ­– additional data expected mid-year and year-end 2024 Evaluation of novel mRNA-launched eVLP (MLE) platform technology underway by...Read more


Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 15
Last Trade: 2.14 -0.02 -0.93

Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE...Read more


STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 15
Last Trade: 0.39 0.02 4.05

HORSHAM, Penn., May 15, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights Revenue in the first quarter of...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB